Royal Group of Pakistan v Mavid Pharmaceuticals Ltd (HCCS 383 of 2010)
Observed later treatment
Citator coverage is limited to judgments in the Wakilii corpus and source-matched treatment records. Absence of a signal is not an assertion that the case remains good law.
AI-generated summary. This summary was generated by AI from the full text of the judgment. It may contain errors or omissions—always read the source judgment before relying on it.
Holding
The High Court dismissed both the plaintiff's claim and the defendant's counterclaim. Held that the plaintiff's suit was res judicata by virtue of a prior winding-up petition settled by consent (Company Cause No. 19 of 2009), which barred all claims arising from transactions prior to that settlement. Held further that the counterclaim was also barred: as against the plaintiff by res judicata; as against the National Drug Authority for being time-barred and misconceived because remedies should have been sought by judicial review within three months under the Judicature (Judicial Review) Rules; and as against the second counter-defendant because it depended on claims against the other parties which had failed.
Outcome
Both the plaintiff's claim for debt and damages and the defendant's counterclaim for loss of business and declarations were dismissed on the ground of res judicata and procedural bars.
Facts
The plaintiff, a Pakistani pharmaceutical supplier, had a 15-year trading relationship with the defendant, a Ugandan distributor who was also the plaintiff's Local Technical Representative (LTR) with the National Drug Authority. In 2006 the parties and others formed a joint venture, Mavid Pharma East Africa Ltd, which was later closed by memorandum of understanding in November 2007. Under that memorandum, the defendant took stock valued at US$267,000 and agreed to a payment plan and a monthly turnover of US$80,000 for two years. The defendant made partial payment, leaving a balance owing. Relations deteriorated. The plaintiff terminated the LTR status in November 2008 and appointed Abacus Pharma (Africa) Ltd as the new LTR, which the National Drug Authority approved in March 2009 over the defendant's objections. In April 2009 the plaintiff filed a winding-up petition (Company Cause No. 19 of 2009) for US$23,439.70, which was settled by consent in November 2009, with the defendant paying the claimed amount. The plaintiff then filed this suit in October 2010 claiming further sums for debts and loss of business. The defendant counterclaimed for loss of business and damages arising from the alleged illegal termination of its LTR status.
Issues
- Whether the Defendant/counterclaimant is indebted to the Plaintiff in the amount claimed?
- Whether the approval of the second counter Defendant as the LTR to the first counter Defendant was done legally?
- Whether the Plaintiff is liable to the counterclaimant/Defendant for loss of business due to cancellation of the LTR status?
- What remedies are available to the parties?
Orders
- The Plaintiff's suit is dismissed with costs.
- The Counterclaimant's action against the three Counter Defendants is dismissed with costs.
- The suit by Suleiman Bukenya discloses no cause of action against the Counter Defendants and the Plaint by way of counterclaim is rejected with no order as to costs.
Rules and key headnotes
Legislation cited (24)
- National Drug Policy and Authority Act cap 206 s.3
- National Drug Policy and Authority Act cap 206 s.5
- Companies Act cap 110 s.224
- Companies Act cap 110 s.226
- Companies Act cap 110 s.227
- Companies Act cap 110 s.231
- Companies Act cap 110 s.232
- Companies Act cap 110 s.243
- Companies Act cap 110 s.244
- Companies Act cap 110 s.262
- Companies Act cap 110 s.263
- Civil Procedure Act s.7
- Civil Procedure Act s.2
- Civil Procedure Rules Order 8 r.2
- Civil Procedure Rules Order 8 r.7
- Civil Procedure Rules Order 8 r.12
- Civil Procedure Rules Order 15 r.1
- Civil Procedure Rules Order 38 r.8
- Evidence Act s.101
- Evidence Act s.102
- Judicature Act s.33
- Judicature Act s.36
- Judicature (Judicial Review) Rules, 2009 r.3
- Judicature (Judicial Review) Rules, 2009 r.5
Cases cited (20)
- Gulaballi Ushillani v Kampala Pharmaceuticals Ltd (Supreme Court Civil Appeal No. 6 of 1998)
- Kamunye and Others v Pioneer General Assurance Society Ltd [1971] EA 263
- Interfreight Forwarders (U) Ltd v East African Development Bank (Supreme Court Civil Appeal No. 33 of 1992)
- Rutaama Godfrey & Misango Abel v Attorney General and Apac District (Court of Appeal Civil Appeal No. 80 of 2012)
- Brooke Bond (T) Ltd v Mallya [1975] EA 266
- Hassanali v City Motor Accessories and Others [1972] EA 423
- Huddersfield Banking Company Ltd v Henry Lister and Sons Ltd (1895) 2 Ch 273
- National Drug Authority v Parkview Pharmacy DC Ltd (Civil Appeal No. 65 of 2000)
- Semakula v Magala & Others [1979] HCB 90
- Frederick Zaabwe v Orient Bank Ltd (Supreme Court Civil Appeal No. 4 of 2006)
- Amama Mbabazi v Yoweri Kaguta Museveni and Others (Presidential Election Petition No. 1 of 2016)
- CSI International Company Ltd v Archway Personnel (Middle East) Ltd [1980] 3 All ER 215
- Hale v Victoria Plumbing Co Ltd and En-Tout-Cas Co Ltd [1966] 2 All ER 672
- Auto Garage v Motokov (1971) EA 514
- Attorney General v Major General David Tinyefunza (Supreme Court Constitutional Appeal No. 1 of 1997)
- Narattan Bhatia v Boutique Shazim Ltd (Supreme Court Civil Appeal No. 16 of 2009)
- Dawson v Bingley Urban Council [1911] 2 KB 149
- De Falco v Crawley Borough Council [1980] 1 QB 460
- Morgan & Sons Ltd v S Martin Johnson & Co Ltd
- Frostmark EHF (suing through Attorney John Kabandize) v Uganda Fish Packers Ltd (HCCS No. 170 of 2010)
Cases citing this judgment (1)
How later Ugandan judgments in the Wakilii corpus have cited this case. Treatment labels come from Sequitur — Uganda’s citator — each backed by a verbatim span from the citing judgment, and are not an assertion that this case is, or is not, good law.
Full judgment
The original judgment as reported. Read the original PDF before relying on any passage.